GEA Pharma System’s ConsiGma™ 1 R&D process is designed to allow you to test and develop individual process steps with a minimal amount of product, on small scale equipment, but using the same parameters required on production equipment such as the ConsiGma 25. Through a collaborative partnership, GEA Pharma Systems and Perceptive Engineering have developed a “bolt on” software solution that

Batch Crystallisation New techniques for 'golden batch' identification, trajectory control and end-point prediction deliver more consistent quality, faster turnaround and less waste. Traditional control often uses fixed recipes and cool-down profiles, with little or no integration of data from PAT devices. Result: lower yield, high variability in particle size. Perceptive's PharmaMV platform

Hot Melt Extrusion (HME) is an emerging technology for the continuous manufacture of pharmaceutical drugs across a wide range of dosage forms, include solid dose formulations which are particularly useful for poorly soluble APIs. HME facilitates the Quality by Design (QbD) approach to pharmaceutical manufacturing through the integration of inline PAT tools for advanced process monitoring and

Reduce operating costs by up to 35% Pfizer Inc has launched their Portable Continuous Miniature and Modular (PCMM) autonomous manufacturing unit for continuous oral solid dose form production. The equipment fits in a portable facility that can be shipped to any location, enabling medicines to be manufactured where and when they are needed. The advantages of PCMM are significant: Reduced

Wet Granulation Reduce variability of finished product quality by up to 30 % Variables such as binder addition rate, screw speed and feeder rates are simultaneously adjusted, to achieve the multiple goals of optimum production rate, on-spec moisture and high levels of drug uniformity. Further, this responsive control system is better able to handle variations in raw material quality,

Novel Continuous Reactors represent the next stage of manufacturing evolution, but bring a unique set of challenges. Very short residence times test the limits of PAT instrumentation. High turn-down rates present a very broad range of 'normal' operating conditions. High feedstock costs impose limits on development and testing runs. The units are designed to run multiple different products,